MARKET

RVNC

RVNC

Revance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.32
+0.36
+1.50%
After Hours: 24.32 0 0.00% 16:00 12/04 EST
OPEN
24.26
PREV CLOSE
23.96
HIGH
24.48
LOW
23.84
VOLUME
237.52K
TURNOVER
--
52 WEEK HIGH
34.62
52 WEEK LOW
11.78
MARKET CAP
1.62B
P/E (TTM)
-5.2849
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 5d ago
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 6d ago
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Zacks · 11/27 18:31
FDA defers BLA decision on Revance's frown lines treatment
Revance Therapeutics (RVNC) -2.8% pre-market after the Food and Drug Administration has deferred a decision on the biologics license application for DaxibotulinumtoxinA for Injection, the company's investigational treatment of moderate
Seekingalpha · 11/25 14:12
FDA Defers Approval Of DaxibotulinumtoxinA For Injection In Glabellar Lines Due To COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
Benzinga · 11/25 13:33
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 11/25 12:35
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has deferred a decision on the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar (frown) lines.
BusinessWire · 11/25 10:30
Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Business Wire · 11/24 21:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RVNC. Analyze the recent business situations of Revance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RVNC stock price target is 35.80 with a high estimate of 55.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 199
Institutional Holdings: 55.53M
% Owned: 83.44%
Shares Outstanding: 66.55M
TypeInstitutionsShares
Increased
64
2.50M
New
33
-67.49K
Decreased
38
3.60M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.62%
Pharmaceuticals & Medical Research
+1.62%
Key Executives
Chairman/Independent Director
Angus Russell
President/Chief Executive Officer/Director
Mark Foley
Chief Financial Officer
Tobin Schilke
Chief Operating Officer
Abhay Joshi
Senior Vice President/General Counsel/Secretary
Dwight Moxie
Other
Dustin Sjuts
Director
Aubrey Rankin
Independent Director
Jill Beraud
Independent Director
Robert Byrnes
Independent Director
Julian Gangolli
Independent Director
Phyllis Gardner
Independent Director
Chris Nolet
Independent Director
Philip Vickers
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RVNC
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.